Use of a Commercially Available Microarray to Characterize
Antibiotic-Resistant Clinical Isolates of Klebsiella pneumoniae by Charnock, Colin et al.
1 
 
Use of a Commercially Available Microarray to Characterize 1 

































A commercially available microarray (IDENTIBAC AMR-ve) for the detection of antibiotic resistance 33 
determinants was investigated for its potential to genotype 30 clinical isolates and two control strains of 34 
Klebsiella pneumoniae. Resistance profiles and the production of extended spectrum β-lactamases were 35 
determined by disc diffusion and the results were compared with the microarray profiles in order to assess its 36 
scope and limitations. Genes associated with resistance to a wide-range of antibiotics, including current first line 37 
therapy options, were detected. In addition, the array also detected class 1 integrases. The array is easy to use and 38 
interpret, and is useful in providing a general description of the numbers and types of resistance determinants in 39 
K. pneumoniae. It also provides an indication of the potential for resistance gene acquisition. However, in most 40 
instances detected resistance to specific antibiotics could not unequivocally be assigned to hybridization with a 41 
specific array probe. We conclude that the microarray is a valuable and rapid means of investigating the presence 42 
of resistance gene-classes of therapeutic importance. It can also provide a starting point for selecting analyses of 43 


























Infections caused by drug-resistant bacteria are a major problem worldwide. Resistance to antimicrobial agents 68 
by members of the Enterobacteriaceae including Klebsiella pneumoniae is of particular concern. K. pneumoniae 69 
is encountered as a saprophyte in humans and other mammals, colonizing the gastrointestinal tract, skin, and 70 
nasopharynx [29]. It can cause a wide range of infections including those of the urinary and lower biliary tracts, 71 
as well as of surgical wounds and the blood stream. In recent years, K. pneumoniae has become established as an 72 
important cause of nosocomial infections, acquiring resistance to antibiotics through plasmid-encoded extended-73 
spectrum β-lactamases (ESBLs), along with a variety of genes conferring resistance to other drug classes. The 74 
most prevalent ESBLs in K. pneumoniae are CTX-M enzymes belonging to Ambler class A [3]. In general, these 75 
enzymes have hydrolytic activity against penicillins, extended-spectrum cephalosporins (e.g. cefotaxime and 76 
ceftazidime) as well as monobactams (aztreonam), but are generally not effective against cephamycins (e.g. 77 
cefoxitin) and carbapenems [25]. The activity against ceftazidime is variable between the different CTX-M types 78 
and certain variants also have activity against 4th generation cephalosporins (e.g. cefepime) [10]. Since the initial 79 
isolation of CTX-M-1 from a European patient in the late 1980s [8], >170 CTX-M allelic variants have been 80 
identified [https://www.ncbi.nlm.nih.gov/projects/pathogens/beta-lactamase-data-resources/]. CTX-M variants 81 
can be divided into 5 major phylogenetic groups, CTX-M group 1, CTX-M group 2, CTX-M group 8, CTX-M 82 
group 9 and CTX-M group 25 on the basis of their amino acid sequences [32 and references therein].  83 
Tzouvelekis et al., [29] noted that a successive addition of genetic elements encoding resistance to 84 
aminoglycosides and ESBLs, coupled with the rapid accumulation of chromosomal mutations conferring 85 
resistance to fluoroquinolones, left carbapenems as of around the year 2000, as the first-choice drugs for the 86 
treatment of health care-associated infections caused by K. pneumoniae. Subsequently there has been a rapid 87 
dissemination of multidrug-resistant (MDR) K. pneumoniae strains producing carbapenemases encoded by 88 
transmissible plasmids. The clinically most important carbapenemases include the class A enzymes of the KPC 89 
group, zinc-dependent class B metallo-β-lactamases, represented mainly by the VIM, IMP, and NDM types, and 90 
class D carbapenemases of the OXA-48 class [reviewed in 29]. Carbapenem-resistant K.  pneumoniae (CRKP) 91 
have emerged as an important cause of morbidity and mortality from hospital-acquired and long-term care–92 
associated infections [15, 20]. Few antimicrobial therapy options now exist for infections caused by CRKP [26]. 93 
The present study evaluates the potential for a commercially available DNA microarray to rapidly and 94 
correctly detect resistance genes of clinical importance in K. pneumoniae. Furthermore, the scopes and 95 
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limitations of the array technique in explaining the results from antimicrobial susceptibility testing were 96 
evaluated. The DNA-based assay [IDENTIBAC AMR-ve Genotyping kit Version 05; CLONDIAG/ALERE, 97 
GmbH] was developed and validated for the parallel detection of resistance and integrase genes in Escherichia 98 
coli and Salmonella [5], but has not been much used with K. pneumoniae. Card et al., [9] report the use of an 99 
extended array, containing many of the same probes as AMR-ve, in the typing of K. pneumoniae (34 strains 100 
distinct from those in the present study), and other Enterobacteriaceae. Other studies have screened respectively 101 





















Materials and methods  121 
 122 
Isolates and control strain 123 
The strain collection consisted of 30 clinical K. pneumoniae isolates. Strains were supplied by the Norwegian 124 
National Advisory Unit on Detection of Antimicrobial Resistance (Tromsø, Norway). K. pneumoniae ATCC 125 
700603 (SHV-18-β-lactamase producing) and K. pneumoniae ATCC 33495 (non-ESBL-producing) were used 126 
for control purposes. 127 
Antibiotic resistance testing 128 
Disc diffusion assays were performed and interpreted according to version 6.0 of the recommendations of the 129 
European Committee on Antimicrobial Susceptibility Testing (EUCAST, http://www.eucast.org). In brief, 130 
susceptibility testing was done using Mueller–Hinton agar (Oxoid, Basingstoke UK). The inoculum was made 131 
from cells grown at 37 ± 1 °C for 18-24 h on tryptone soya agar (TSA, Oxoid) and adjusted to 0.5 McFarland. 132 
After applying antibiotic discs (Oxoid), plates were incubated at 35 ± 1 °C for 16-20 h prior to the reading of 133 
zone diameters. Based on zone diameters, strains were recorded as susceptible (S), intermediate susceptible (I) or 134 
resistant (R) to each antibiotic according to the guidelines.    135 
The following antibiotics and concentrations were tested:  ampicillin (AMP, 10 µg), amoxicillin/clavulanate 136 
(AMC, 30 µg), piperacillin/tazobactam (TZP, 30/6 µg), cefotaxime (CTX, 5 µg), cefoxitin (FOX, 30 µg), 137 
ceftazidime (CAZ, 10 µg), cefuroxime (CXM, 30 µg), meropenem (MEM, 10 µg), ciprofloxacin (CIP, 5 µg), 138 
gentamicin (CN, 10 µg), trimethoprim-sulphamethoxazole (SXT, 25 µg) and aztreonam (ATM, 30 µg). 139 
Disc-diffusion screening for β-lactamase production 140 
Phenotypic detection of ESBLs was performed on all strains using a double disc synergy test consisting of 141 
cefpodoxime 10 µg and cefpodoxime/clavulanic acid 10/1 µg (Combination kit DD0029; Oxoid). An increase of 142 
≥ 5mm between the cefpodoxime and cefpodoxime/clavulanic acid discs was interpreted as a positive test 143 
according to the manufacturer’s instructions. Based on indications from disc diffusion susceptibility and 144 
microarray testing, some isolates were also screened for the presence of metallo-β-lactamases and KPC enzymes 145 
(class A)  using the KPC/MBL Confirm Kit (ROSCO, Denmark) and the ESBL and AmpC Screen kit (ROSCO) 146 
according to the manufacturer’s instructions. All tests were performed using Mueller-Hinton agar (Oxoid) as 147 
described for the antibiotic susceptibility testing. 148 
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AMR-ve Microarray 149 
A DNA-based assay (IDENTIBAC AMR-ve Genotyping kit Version 05; CLONDIAG/ALERE, GmbH) with 89 150 
probes for different genetic markers including resistance gene families and integrases was used. The kit is able to 151 
detect ~57 antimicrobial resistance genes in Gram-negative bacteria, including several ESBLs. Basic details of 152 
the method and the probes used are given in the original publication [5] and the kit protocol (available at 153 
www.identibac.com). In brief, K. pneumoniae was grown for 18-24 h at 37 °C on TSA. Genomic DNA was 154 
isolated from a 1mm loopfull of cells (about 1 ×109 cells) using the DNeasy® Blood and Tissue set (Qiagen, 155 
Venlo, Netherlands) as previously described [12]. The DNA concentration and purity were determined using a 156 
Nanodrop-100 spectrophotometer (NanoDrop, DE, USA), and the DNA integrity and absence of intact RNA was 157 
checked by agarose electrophoresis. About 0.75 µg DNA was made up in 5 µl ultrapure molecular biology grade 158 
water (Sigma Aldrich) [concentration, 0.15 µg/µl]. PCR, biotin labeling, hybridization to arrays, washing and 159 
development of spots were performed as described in the AMR-ve protocol.  Signal intensities were read within 160 
10–15 min. of the final step (addition of buffer D1). Arrays were aligned in the reader as required by manual 161 
setting of array reference marker spots as described in the ATR03 2.0 installation and user guide. Results were 162 
exported, and the mean signal value for 3 replicate spots per probe was determined manually. Probes with 163 
intensity value ≥ 0.4 were considered positive (P in tables) whilst those <0.3 were considered negative. Values 164 


















Overview of the results of microarray testing and the most common resistance determinants in K. 181 
pneumoniae 182 
Fig. 1 provides a summary of the results from the microarray tests. Table 1 shows resistance phenotypes based 183 
on disc diffusion assays. All strains were positive for one or more genetic marker in the microarray. Among the 184 
30 clinical isolates tested, hybridization with probes associated with resistance to the following antibiotics was 185 
obtained for one of more strains: β-lactams, sulphonamides, trimethoprim, tetracyclines, aminoglycosides, 186 
quinolones and chloramphenicol. In addition, hybridization with a probe indicating the presence of a class 1 187 
integrase was obtained with 18 clinical isolates (60%) and both control strains. Thus the assay was able to detect 188 
simultaneously resistance markers to a wide-range of antibiotic groups of clinical importance for the treatment of 189 
infections caused by K. pneumoniae, as well as a genetic element associated with resistance-gene acquisition. 190 
The most commonly detected resistance determinants 191 
By virtue of a relatively large number of probes representing multiple antibiotic classes, the microarray was able 192 
to provide an overview of which resistance gene classes were common among the clinical isolates and control 193 
strains. The 5 most commonly detected resistance markers in the 30 clinical isolates were consensus-blaSHV (β-194 
lactams; 87%), tetA (tetracycline; 67%), sul1 (sulphonamides; 60%), consensus-blaTEM (β-lactams; 53%) and 195 
blaCTX-M-l-like (β-lactams; 47%).   196 
Resistance to β-lactams 197 
All strains were resistant to ampicillin, 90% of the clinical isolates were intermediate susceptible or resistant to 198 
cefuroxime (2nd generation cephalosporin), and 90% were intermediate susceptible or resistant with respect to 199 
cefotaxime (3rd generation cephalosporin). All strains gave hybridization with one or more probes representing 200 
classes of resistance determinants to β-lactams. Four clinical isolates and the control strain ATCC 700603 did 201 
not produce hybridization with the consensus-blaSHV-1-probe. However, these gave hybridization with other 202 
determinants of resistance to β-lactams, variously consensus-blaTEM and/or one or more of the blaCTX and blaOXA-203 
probes. Hybridization to the blaCTX-M-1-like probe was common (Fig. 1), supporting the idea that the class A 204 
CTX-M β-lactamases are widespread among clinical isolates of the species. All strains possessing a blaCTX-M 205 
determinant were resistant to cefuroxime and cefotaxime.  206 
Testing for β-lactamase production 207 
Detection of ESBLs:  208 
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ESBLs were detected in isolates 5-9, 12-20, 22-26, and 30, but not in 21, 27-29. These results correlate well or 209 
are not excluded by the disc-diffusion and microarray-based tests (Table 1; Fig. 1).  210 
KPC/MBL-kit (Rosco) and resistance to meropenems: 211 
Based on the finding of resistance to meropenem, isolates 1-4 (Table 1), were chosen as relevant for screening 212 
for KPC (or other class A enzyme) and MBL (Ambler class B) production. Strains 1, 2 and 3 were shown to be 213 
MBL producers, whereas strain 4 did not possess an MBL. Strain 4 tested positive for KPC (or other Ambler 214 
class A enzyme).  The finding of resistance/intermediate susceptibility to meropenem in these strains  215 
is thus supported by the confirmatory tests.  216 
ESBL+AmpC-screen test (Rosco): 217 
Isolates 10 and 11 hybridized with respectively probes detecting DHA and FOX/CMY resistance determinants 218 
(Fig. 1). These were the only strains where a plasmid-mediated class C β-lactamase was indicated by the array. 219 
In a previous array-based study of 29 K. pneumoniae clinical isolates, hybridization to the DHA- and FOX-220 
probes was not found, and only 3 instances of hybridization to the CMY-probe was obtained. However, these 221 
genes were also only sporadically found in other species of Enterobacteriaceae [9]. In the present work, testing 222 
of strains 10 and 11 using the ESBL+AmpC screen, confirmed AmpC activity in isolate 10. The results were 223 
ambiguous with strain 11 perhaps owing to the presence of multiple β-lactamases (Fig. 1). 224 
Resistance to tetracycline (tet) 225 
Disc diffusion tests were not performed for tetracycline resistance as EUCAST zone diameter breakpoints are 226 
only validated for Escherichia coli. The most common determinant of resistance to tetracyclines detected was 227 
tetA (detected in 67% of clinical  isolates). In addition tetD was detected in 3 isolates, whereas tetB was only 228 
detected in the control strain ATCC 33495.  229 
Resistance to sulfonamides (sul) and trimethoprim (dfr) 230 
Eighty-seven percent of the clinical isolates were resistant/intermediate susceptible to SXT. Hybridization to 231 
sul1 was obtained for 60% of the clinical isolates and both control strains, whereas the corresponding number for 232 
sul2 and sul3 was 40% and 3%, respectively (Fig. 1). The four SXT susceptible strains lacked both sul and dfr 233 
(n=3) or only dfr (n=1). Consequently, the results of the phenotypic susceptibility testing are in accordance with 234 
the microarray findings. However, resistance to SXT was found in 5 strains producing hybridization with sul or 235 
dfr (but not both) and in one which did not hybridize to sul or dfr (Fig. 1; Table 1).  236 
Resistance to the aminoglycoside gentamicin 237 
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Twelve of the 30 clinical isolates (40%) were resistant to gentamicin. The array has 7 probes dedicated to the 238 
detection of determinants of aminoglycoside resistance. Of these, Prob_aac3Ia_1, Prob_aac3IVa_1 (3-N-239 
aminoglycoside acetyltransferases) and probe_ant2Ia_1 (aminoglycoside 2’’-adenyltransferase) are generally 240 
associated with gentamicin resistance [19]. However, none of the clinical isolates produced hybridization with 241 
the two first-named probes. Hybridization with probe_ant2Ia_1 was obtained only with the control strain ATCC 242 
700603 which also showed intermediate susceptibility to gentamicin (Table 1). Of the 12 resistant clinical 243 
isolates, 10 (83%) produced hybridization with probe Prob_aac6Ib_1 which is associated with an 244 
aminoglycoside 6’-N-acetyltransferase. In addition, 3 gentamicin-susceptible strains gave hybridization to this 245 
probe.  246 
Resistance to the fluoroquinolone ciprofloxacin. 247 
Sixty-three percent of the clinical isolates showed resistance or intermediate susceptibility to ciprofloxacin 248 
(Table 1). Of these 19 strains, only 68% hybridized with one or more of the qnr-probes associated with low-level 249 






















This study describes the first systematic and extensive application of the commercially available AMR-ve 270 
microarray to the determination of resistance determinants and integrases in clinical K. pneumoniae isolates. 271 
AMR-ve has been used to characterize one [27] and two [31] K. pneumoniae in other studies. Data from testing 272 
of a non-overlapping set of 29 clinical isolates and 5 control strains of K. pneumoniae using an extended version 273 
of the array containing many of the same probes has been reported [9] and comparisons are discussed below. The 274 
array was able to detect quickly and generally unambiguously, resistance determinants to all the major groups of 275 
clinically important antibiotics in the treatment of K. pneumoniae. Of the total of 265 individual probe 276 
hybridizations recorded for the 32 strains, only 7 reactions (< 3%) were recorded as ambiguous (given as yellow 277 
cells in Fig. 1).  278 
The array requires 100 – 400 ng/µl DNA (total volume 5 µl) from a single clone for linear amplification 279 
prior to hybridization. This is, of course, less sensitive than a classical PCR approach where typically a few ng of 280 
template DNA is required. However, array-based approaches such as AMR-ve have the advantage of being able 281 
to detect many more genes (> 50 in the present study) than for example a standard multiplex PCR-analysis. 282 
Furthermore, as high as a 98.8% correlation between the array and PCR-data has been reported [5].  283 
Salient details concerning the origins of the array probes and the resistance determinants they may 284 
reveal are given in Table 1 in the original publication describing the development of the array [5]. Amr-ve was 285 
originally developed for and validated against Escherichia coli and Salmonella spp.  One indication of the 286 
applicability of AMR-ve to typing of K. pneumoniae comes from the observation in the present and previous 287 
work [9], that most of the array probes gave hybridization with one or more K pneumoniae. However, the 288 
following 13 probes did not hybridize with any strain in either study: tetE, tetG (associated with tetracycline 289 
resistance); aadA4, aac(3)-Ia, aac(3)-IV (associated with aminoglycoside resistance); dfrA7, dfrA17 (associated 290 
with resistance to trimethoprim), blaMOX, blaACC-1, blaOXA-7. blaCTX-M2, blaCTX-M8, bla CTX-M-26 (associated with 291 
reistance to β-lactams). This and other concordances between the present and previous work on non-overlapping 292 
sets of strains, probably reveals important information on the typical genetic makeup of drug-resistant K. 293 
pneumoniae. However, in cases of non-hybridiaztion probe suitability might also be an issue. To assess this we 294 
compared probe sequences [5] to those in the GenBank® database using the BLAST® search engine [2]. The 295 
search was restricted to generally curated K. pneumoniae DNA and the resistance gene in question. Of the 13 296 
array-probes which did hybridize to any strain, we found in the database several instances of 100% sequence 297 
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identity over the whole probe length for all but tetE (probe length 24 bp; sequence identity only over 15 bp). The 298 
tetC-probe which did not hybridise with any of the strains investigated in the present study gave similar results to 299 
tetE (probe length 24 bp; sequence identity only over 14 bp). However, in the study of Card et al., [9], 17% of 300 
clinical isolates produced hybridization to this probe. More data is desirable in order to evaluate the limitations 301 
of these probes in the investigation of resistance to tetracycline in K. pneumoniae.  302 
In addition to the detection of a wide-range of resistance determinants to antibiotic classes with 303 
relevance to the treatment of infections caused by K. pneumoniae, the array also detected class 1 integrases in 304 
60% of the clinical isolates and both control strains. This is similar to the value of 83% for other clinical isolates 305 
of the species [9] and 74% reported for multidrug resistant K. pneumoniae and Escherichia coli in Iran [28]. 306 
Furthermore, in a study of 136 clinical isolates of K. pneumoniae in India, 52 of 63 ESBL-producing isolates 307 
(83%) contained a class 1 integrase [6]. The finding of a significant distribution of class 1 integrases in the 308 
present and other studies, supports the notion that a potential for resistance gene acquisition is common in 309 
clinical isolates of this species. Some of the studies referenced above [6, 28] used multiplex-PCR-based 310 
procedures for the detection of integrases. The present study shows that similar screening can be done effectively 311 
with the AMR-ve approach. 312 
The most commonly indicated resistances were blaSHV (87% clinical isolates), tetA and sul1. The blaSHV 313 
gene is chromosomally located in K. pneumoniae [13] and it has been suggested that SHV enzymes approach 314 
ubiquity in K. pneumoniae [4]. The finding that the majority of clinical isolates produced hybridization with 315 
blaSHV is thus in keeping with previous work. However, the blaSHV-probe included on the array is a consensus 316 
sequence for blaSHV-genes and this limitation of scope is discussed further below. It has been reported that tetA 317 
encoded efflux pumps are widespread among Enterobacteriaceae [32], but there is limited data for K. 318 
pneumoniae. In an analysis of 30 K. pneumoniae causing urinary tract infections in Iran [7], all of the isolates 319 
tested positive for tetA and tetB. This is in line with the present array results. However, in contrast to the Iranian 320 
strains, the present study strongly suggests that tetA (67% Norwegian clinical isolates) is more common than tetB 321 
(0%) in Norway. In their study of 29 isolates, Card et al., [9] found that only 21% of K. pneumoniae hybridized 322 
with tetA, again suggesting significant clonal differences with respect to this gene. Alternatively the low rate of 323 
detection of tetB might be due to mutations/mismatches in the area of the probe. This could be investigated 324 
further by sequencing studies. 325 
β-lactam antibiotics are the most important agents in the therapy of K. pneumoniae infections, and the 326 
array’s standard set of probes is suitably dominated by those detecting determinants of resistance to these 327 
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antibiotics. The assay has only a single, consensus probe for blaSHV genes. SHV-enzymes can, however, be both 328 
narrow spectrum and extended-spectrum (ESBLs), depending on the subtype in question [17, 18]. Concordances 329 
between hybridization with Prob_shv1_11 and measured resistances to cephalosporins and aztreonam illustrate 330 
some of the limitations of the AMR-ve system: ten of the strains tested gave hybridization with only 331 
Prob_shv1_11 from among the array’s set of probes for β-lactam resistance genes (Table 2). If SHV-enzymes are 332 
responsible for the β-lactam resistance phenotypes shown in Table 2, the array is unable to distinguish between 333 
what is probably a classical narrow-spectrum enzyme in the control strain ATCC 33495, and the broad-spectrum 334 
enzymes present in for example strains 8 and 14.  Such a differentiation (subtyping) which is most useful to the 335 
researcher can be accomplished by the PCR-sequencing approach, but is a limitation of the array in its present 336 
form. In contrast to the single determinant for SHV-enzymes, the array contains several probes hybridizing to 337 
blaCTX-M-genes. For 14 clinical isolates, positive signals were obtained with Prob_ctxM1_11. This probe detects 338 
among others the phylogenetic group CTX-M-15 which is currently the most widely disseminated CTX-M type 339 
in the world [21].  Antibiotic resistances assayed by the disc diffusion assay were in general agreement with the 340 
expected effects of the presence of blaCTX-M- genes (Table 1; Fig. 1). CTX-M-type ESBLs can exhibit activity 341 
against monobactams and extended spectrum cephalosporins, including cefotaxime and ceftriaxone, but are 342 
classically less effective against ceftazidime, cephamycins (e.g. cefoxitin) or carbapenems [3]. Thus, the finding 343 
that the majority of clinical isolates (87%) were resistant or intermediately susceptible to ceftazidime (Table 1) is 344 
somewhat surprising. However, the classical pattern of resistance conferred by CTX-M is not universal since 345 
mutations can alter the specificity of CTX-enzymes [14]. Some CTX-M sub-types (e.g. CTX-M-15) have greater 346 
catalytic efficiency against ceftazidime [8]. This sub-type is for example detected along with others by the array 347 
ctxM1_11 probe. Given this, a more stringent probe, if practically feasible, directed at ceftazidime resistance 348 
related CTX-M sub-types would be useful. Incidences of ceftazidime resistance/ intermediate susceptibility in 11 349 
clinical isolates (Table 1) not showing hybridization with the ctxM1_11 probe, could potentially also be 350 
explained by mutations in common plasmid-mediate SHV (or TEM) genes producing ESBLs [8].  Over-351 
production of SHV-enzymes (all 11 isolates produced hybridization with the blaSHV-probe) and/or changes in 352 
outer-membrane protein changes have also been associated with reduced susceptibility to ceftazidime in K. 353 
pneumoniae [22, 23].  354 
Carbapenems are in some instances the last therapeutic options for treatment of infections by K. 355 
pneumoniae. It is, therefore, pertinent to look more closely at the results for the 4 strains (strains 1-4; Table 1) 356 
which showed meropenem resistance/intermediate susceptibility. Although it includes probes detecting various 357 
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classes of Ambler A and C enzymes, the AMR-ve system is not equipped to detect determinants of class B 358 
enzymes.  Thus the array is not able to provide support for the finding of MBLs (detected phenotypically) in 359 
strains 1, 2 and 3. Furthermore the array does not detect blaKPC which would be useful given that KPC activity 360 
was detected for strain 4.  361 
Plasmid-mediated resistance to sulphonamides and trimethoprim is normally due to the acquisition of 362 
dihydropteroate synthases for sulphonamides and dihydrofolate reductases for trimethoprim. Three resistance 363 
genes, sul1, sul2 and sul3 encoding dihydropteroate synthases and more than 20 dihydrofolate reductase (dfr) 364 
genes have been described [16]. Both groups of genes are associated with class 1 integrons residing on plasmids 365 
and/or the chromosome [16]. The array shows 100% correlation between susceptibility to SXT and the absence 366 
of hybridization to dfr and/or sul probes. However, 5 SXT-resistant strains did not produce hybridization with 367 
either one or both of sul and dfr probes, possibly indicating the presence of other resistance 368 
determinants/mechanisms not detected by the microarray. In summary, the microarray was able to explain 369 
sensitivity but not always resistance to SXT.   370 
The present study suggests that an aminoglycoside 6’-N-acetyltransferase may be associated with 371 
gentamicin resistance in the current panel of strains: thirteen clinical isolates produced hybridization with this 372 
probe (Fig. 1). Of these, 77% showed resistance to gentamicin (Table 1). Similarly, in a previous study of K. 373 
pneumoniae isolates [9], it was found that 76% of strains producing hybridization to the probe were also resistant 374 
to gentamicin. However, although AAC(6’)-Ib is the most prevalent aminoglycoside-modifying enzyme known, 375 
and is present in over 70% of AAC[6’]-producing Gram-negative isolates [30], group I type 6’-N acetyl 376 
transferases are not typically agents of resistance to gentamicin [19, 30]. In one study of carbapenem-resistant K. 377 
pneumoniae, 98% of strains tested possessed aac(6’)-Ib [1]. However, this gene was associated with resistance to 378 
tobramycin and not to gentamicin. In addition, about 94% of the strains that carried aac(6’)-Ib as the only 379 
determinant of an aminoglycoside-modifying enzyme were susceptible to gentamicin [1]. The authors thus 380 
proposed that aac(6’)-Ib in association with other aminoglycoside resistance genes could explain the high 381 
gentamicin MIC values found for some strains. Furthermore, they suggest that the widespread presence of 382 
aac(6’)-Ib in K. pneumoniae could be a consequence of it being on the same plasmids as those carrying ESBL 383 
genes [1].  In the present study, the four clinical isolates which did not produce ESBLs (phenotypic tests) also 384 
failed to give hybridization to Prob_aac6Ib_1, whereas every strain producing hybridization with Prob_aac6Ib_1 385 
was also an ESBL producer. Thus the array test provides some support for the proposed presence of aac(6’)-Ib 386 
and ESBL-genes on the same plasmids [1]. Notwithstanding, it should be noted that some aac(6’)-Ib subvariants 387 
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are known to be associated with gentamicin resistance. Among the recent variants of this enzyme with altered 388 
specificity are AAC(6’)-Ib11, which confers simultaneous resistance to gentamicin and amikacin [11] and 389 
AAC(6’)-Ib-cr, which has a unique extension of its substrate specificity from aminoglycosides to structurally 390 
unrelated fluoroquinolones [24]. If feasible, it would be useful to include additional probes in order to ascertain 391 
if the apparent correlation between gentamicin resistance and hybridization to Prob_aac6Ib_1 - probe aac (6’)-Ib 392 
in the present study, indicates the presence of gene sub-types conferring gentamicin resistance 393 
Of the 30 clinical isolates tested, 19 showed resistance or intermediate resistance to ciprofloxacin. Of 394 
these, 32% showed resistance to ciprofloxacin without giving hybridization with probes associated with 395 
resistance to quinolones. However, qnr genes are known to only give low-level resistance to quinolones. 396 
Quinolone resistance is mainly caused by chromosomal mutations in gyrA and parC, and the contribution of a 397 
qnr-gene can be additive to other resistance factors. The microarray is thus useful in its ability to detect qnr but 398 
unsurprisingly it is not predicative of resistance to ciprofloxacin. 399 
Susceptibility to chloramphenicol was not investigated in the present study. AMR-ve hybridizations 400 
indicated that the most common determinants of resistance to this antibiotic were chloramphenicol 401 
acetyltransferases (CatB3; CatA1). Genes connected with efflux proteins (FloR; CmlA) were also detected, but 402 
in fewer strains (Fig.1). The same tendency was seen in a previous study of clinical isolates [9]. In the referenced 403 
work, all strains producing hybridization with the catA1-probe and/or the cmlA-probe were also resistant to 404 
chloramphenicol. Thus hybridization with these probes seems to be a good indicator of the resistance phenotype. 405 
Summing up the results, the present study evaluates the usefulness of a commercially available 406 
microarray, AMR-ve, for the detection of clinically important resistance determinants and integrases. The assay 407 
was able to detect genetic determinants of integrases and a wide-range of antibiotic classes of relevance for 408 
treatment of infections caused by K. pneumoniae. Furthermore the test was easy to perform and the results were 409 
only rarely difficult to interpret (‘ambiguous’). AMR-ve functions well in the genotyping of clinical isolates of 410 
K. pneumoniae and provides a useful start point for further testing.  However, the assay was shown to be too 411 
restricted in scope to explain many important measured resistances to β-lactams (e.g. to carbapenems) and 412 
aminoglycosides in K. pneumoniae. The producer of the AMR-ve has recently launched a new CarbDetect AS-1 413 
Kit for multidrug-resistant Gram-negative bacteria which runs on the same platform. This test allows DNA-414 
based detection of amongst others the most important carbapenemase genes (e.g. blaOXA-23, blaKPC, blaNDM, 415 
blaVIM) as well as other prevalent β-lactamases (e.g. blaCTXM-1/15, blaOXA-1, blaOXA-2). It also contains species-416 
specific probes for identification of K. pneumoniae. Thus this new system supplies some of the information 417 
15 
 
needed to bridge gaps between genotyping and resistance testing reported as weaknesses of the AMR-ve in the 418 
present work. Additionally, whole genome sequencing studies are becoming an option for more laboratories and 419 
are offered commercially. These can reveal allelic forms of genes and point mutations which are often 420 
specifically associated with resistance to a particular antibiotic. The current price for the AMR-ve Genotyping 421 
kit is about 1500 EUR for 50 tests (about 30 EUR per bacterium). A single analyst in our laboratory was able to 422 
test about 5-10 strains per day with the AMR-ve. There are now many commercial agents offering whole 423 
genome sequencing at about 300-400 EUR for a single strain with lower prices for bulk orders (including DNA 424 
purification from supplied cells, libraries and bioinformatics) with a turnaround of 3-4 weeks or less. Thus the 425 
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AMC R R R R R  R  R R R R  R       R R  R     R    
TZP R R R R R  I  R R R I  R       R   I   I  R  I  
CTX R R R R R R R R R I R R R R I R R R R R  R R R  R  I R R I  
FOX R R R R       R      R R     R    R R R  R  
CAZ R R R R R  R R R R R R  R I R  R R R I I R R I I  I  I R  
CXM R R R R R R R R R R R R R R  R R R R R  R R R R R  R R R R  
MEM R R I R                             
ATM R R R R R I R R R I R R I R  R R R R R  R  R  R   R R R  
CIP R R R R R  I  R R I R I  I I   R I  R  I  R R      
CN R R   R R R  R R R R R         R  R       I  














Table 2 Overview of resistance phenotypes of strains producing hybridization with either the SHV-1 or the 555 















ATM MEM (I) 
8 Prob_shv1_11 AMP CXM,   
CTX,CAZ 
ATM - 
14 Prob_shv1_11 AMP, AM/C, 
TZP 
CTX, CAZ, CXM ATM - 
15 Prob_shv1_11 AMP CTX(I), CAZ(I) - - 
23 Prob_shv1_11 AMP FOX, CXM 
CTX, CAZ, 
- - 
25 Prob_shv1_11 AMP CXM, CAZ(I) - - 
26 Prob_shv1_11 AMP CTX, CAZ(I), CXM ATM - 
27 Prob_shv1_11 AMP, TZP(I) FOX 
 
- - 






Prob_shv1_11 AMP - - - 
6 Prob_tem1_1 AMP CTX 
CXM 
ATM(I) - 














Fig 1. Heat map showing the pattern of probe hybridizations for 32 strains of Klebsiella pneumoniae. 569 
Only probes giving hybridization to one or more strain are shown.  570 
Key: A – probe associated with class 1 integrases. B – trimethoprim. C – tetracyclines. D – sulphonamides. E – quinolones/fluoroquinolones. 571 
F – chloramphenicol. G – β-lactams. H - aminoglycosides   572 
 573 
